Redcare Pharmacy's Strategic Pivot Confronts a Brutal Retail Onslaught

Redcare's stock recovers 46% as its prescription business surges 35%, but German giants attack its OTC segment, forcing growth and margin cuts.

The stock of European online pharmacy leader Redcare Pharmacy is staging a tentative recovery, yet its management team faces a market undergoing a radical and aggressive transformation. After plummeting to multi-year lows around €31 in late March, the share price has rallied approximately 46%, trading recently at €45.16. This bounce, however, masks a deep strategic schism within the company's operations and an intensifying competitive siege.

A Tale of Two Businesses

The company's performance is a story of divergence. Its core prescription (Rx) business is firing on all cylinders, providing a critical financial buffer. Preliminary Q1 2026 figures show group-wide Rx revenue surged 35% to €315 million. In its home German market, the growth was even more spectacular at 55%, reaching €168 million and handily beating analyst forecasts. Redcare commands a dominant 67% share of the German online prescription market.

Conversely, the lucrative over-the-counter (OTC) segment is under direct assault. German drugstore giants dm and Rossmann are aggressively expanding into the online OTC space, leveraging their massive retail footprints. Rossmann, operating from the Netherlands—Redcare's home turf—boasts a formidable app with around 11 million active users. In response to this mounting pressure, CEO Olaf Heinrich has already slashed the OTC growth forecast from 16% to a range of 8-10% and reduced the medium-term margin target from over 8% to more than 5%. A recent OTC growth rate of 9.7% does little to alter this daunting competitive landscape.

Leadership and Investment at an Inflection Point

This period of market transition coincides with peak investment and a leadership overhaul. The company has declared 2026 its year of maximum capital expenditure, centered on a new logistics hub in Plze?, Czech Republic, operational since November 2025, which boosts annual capacity by 15 million packages. The investment ratio is expected to fall below 2% of sales after 2027.

Simultaneously, a generational shift is underway. The recent Annual General Meeting confirmed a new slate of Supervisory Board members—Anja Hendel, Max Müller, and Peter Schmid von Linstow—and officially appointed Hendrik Krampe as the new CFO. Krampe’s eight-year tenure as Finance Director for Amazon’s European marketplace business is seen as a strategic hire for Redcare’s next growth phase.

Regulatory Tailwinds and Analyst Conviction

A potential regulatory shift could further cement Redcare's advantage in its stronghold. An expert commission has recommended raising statutory co-payments for prescription medicines by 50%, a move Health Minister Nina Warken aims to legislate swiftly. Analysts like Felix Dennl of Bankhaus Metzler view this as a structural boon for mail-order pharmacies, likely driving price-sensitive customers from brick-and-mortar stores to cheaper online alternatives. This dynamic is amplified by Rossmann’s explicit confirmation that it will not enter the prescription medication market.

Despite a share price that remains nearly 67% below its 52-week high of €136.20, analyst optimism is stark. Deutsche Bank reaffirms a "Buy" rating with a €99 price target, while Jefferies is even more bullish at €150. The stock's Relative Strength Index (RSI) reading of 25.1 indicates it is deeply oversold.

All eyes are now on the detailed Q1 report due May 6th. It must demonstrate whether the blistering Rx growth can fully offset the margin compression in the contested OTC arena. Management has reiterated its full-year guidance of 13-15% revenue growth and an adjusted EBITDA margin of at least 2.5%. These figures now serve as the definitive benchmark for a company navigating a brutal competitive offensive while betting big on its own logistical and leadership future.